Advertisement
 
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Novartis Treatment Promising Against Drug-Resistant Lung Cancer

March 27, 2014 10:48 am | News | Comments

Novartis published clinical trial results showing the investigational compound LDK378 (ceritinib) achieved an overall response rate of 58% and a median progression-free survival of seven months in adults with advanced anaplastic lymphoma kinase positive non-small cell lung cancer. Read more...

TOPICS:

Germany's Merck Launches Phase 3 Fertility Study

March 27, 2014 10:35 am | News | Comments

Merck announced the enrollment of the first patient into a new Phase 3 study in the area of fertility, marking another step in its efforts to explore innovative solutions in areas of unmet medical need.  Read more...          

TOPICS:

New Cancer Drug Targets CEA Protein

March 27, 2014 10:17 am | News | Comments

A new cancer drug, based on further development of a discovery originally made by Cancer Research UK, has entered a clinical trial to target a wide range of cancers. Read more...                      

TOPICS:
Advertisement

Takeda, Otsuka to Co-Promote Gastrointestinal Drug in Japan

March 27, 2014 5:26 am | by Takeda | News | Comments

Otsuka Pharmaceutical Co. Ltd. and Takeda Pharmaceutical Co. Ltd. announced that the two firms have entered into a co-promotion agreement in Japan for TAK-438, a drug discovered by Takeda for the treatment of acid-related diseases. Read more...

TOPICS:

Stimulant Drugs Can Impair Neuronal Activity

March 26, 2014 2:38 pm | News | Comments

Researchers have discovered impaired neuronal activity in the parts of the brain associated with anticipatory functioning among occasional 18- to 24-year-old users of stimulant drugs. Read more...                

TOPICS:

Pfizer's Genotropin Hits Phase 3b Endpoints

March 26, 2014 2:09 pm | News | Comments

Pfizer Inc. announced the top-line results from a Phase 3b study evaluating the 24-month efficacy of Genotropin (somatropin) on the height in small-for-gestational-age (SGA) children 24 to 30 months old. Read more...           

TOPICS:

Under Fire, Zohydro Maker Touts Safety Board

March 26, 2014 1:54 pm | by Matthew Perrone, AP Health Writer | News | Comments

After months of criticism over its recently launched painkiller Zohydro, the maker of the powerful narcotic is highlighting an unusual oversight board that it's assembled to try and prevent abuse of the drug. Read more...             

TOPICS:

SwRI Wins $8.3M HHS Grant for Cyanide Antidote Development

March 26, 2014 1:38 pm | News | Comments

The U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority has awarded Southwest Research Institute an $8.3 million contract extension to continue development of a nasal-delivery, first-line treatment system to combat cyanide poisoning. Read more...

TOPICS:
Advertisement

Drugs for Terminally Ill Clear New Hurdle

March 26, 2014 1:05 pm | News | Comments

A proposal to allow terminally ill people access to drugs that are still completing clinical trials cleared its first test in the Colorado Legislature on Tuesday. Read more...                      

TOPICS:

Pharmacists Urged to Withhold Compounded Execution Drugs

March 26, 2014 12:56 pm | by Andrew Welsh-Huggins, AP Legal Affairs Writer | News | Comments

Several human rights and anti-death penalty groups have asked the American Pharmacists Association to prohibit members from participating in executions, a request that comes as states increasingly turn to pharmacists for lethal injection drugs. Read more...

TOPICS:

Gold-Based Drug Shows Promise Against Bone Cancer

March 26, 2014 12:35 pm | News | Comments

A gold-based drug currently used in human and veterinary medicine to manage certain immune diseases may prove useful in combating osteosarcoma, researchers report. Read more...                      

TOPICS:

Immunotherapy Data Heralds New Era of Lung Cancer Treatment

March 26, 2014 12:26 pm | News | Comments

For decades, scientists and doctors thought immunotherapy– treatments that harness the immune system to fight a disease– was of marginal benefit in lung cancer. Now, a new class of drugs known as “immunocheckpoint regulators” have shown huge potential in treating the disease. Read more...

TOPICS:

AM-Pharma Announces Phase 1 AKI Drug Data

March 26, 2014 12:15 pm | News | Comments

AM-Pharma B.V. announced the results of its Phase 1 trial with of recAP (recombinant human Alkaline Phosphatase), showing that both single and multiple ascending doses are safe and well tolerated. Read more...          

TOPICS:

FDA Approves Actavis-Valeant Bacterial Gel

March 26, 2014 12:03 pm | News | Comments

Actavis and Valeant Pharmaceuticals announced that the FDA has approved the New Drug Application (NDA) for Metronidazole 1.3% Vaginal Gel, an antibiotic for the treatment of bacterial vaginosis (BV). Read more...             

TOPICS:

Inovio Snags Best Therapeutic Award at World Vaccine Congress

March 26, 2014 10:05 am | News | Comments

Inovio Pharmaceuticals Inc. announced that it was recognized with three industry awards at the World Vaccine Congress, being held this week in Washington, D.C. Read more...                       

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading